A comparison of continuous intravenous insulin and subcutaneous insulin among patients with type 2 diabetes and congestive heart failure exacerbation

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 1, 2015, Pages 93-101

  Dungan, Kathleen M ^a   Osei, Kwame ^a   Gaillard, Trudy ^a   Moore, Jared ^b   Binkley, Philip ^b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Heart failure; Insulin; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYTOKINE; GLUCOSE; INSULIN GLARGINE; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; GLUCOSE BLOOD LEVEL; INSULIN; INSULIN ASPART; INSULIN LISPRO;

ADULT; ARTICLE; BLOOD GLUCOSE METER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART RATE VARIABILITY; HUMAN; IMPEDANCE; INFLAMMATION; INSULIN HYPOGLYCEMIA; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PARASYMPATHETIC TONE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE; AGED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; DRUG EFFECTS; HEART FAILURE; INSULIN INFUSION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN ASPART; INSULIN INFUSION SYSTEMS; INSULIN LISPRO; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84920972595     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2569     Document Type: Article

References (29)

1. Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-e245.
2. Adams KF Jr, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-216.
3. De Groote P, Lamblin N, Mouquet F, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004; 25: 656-662.
4. Ariza-Andraca CR, Altamirano-Bustamante E, Frati-Munari AC, Altamirano-Bustamante P, Graef-Sanchez A. Delayed insulin absorption due to subcutaneous edema. Arch Invest Med 1991; 22: 229-233.
5. Dungan KM, Binkley P, Nagaraja HN, Schuster DS, Osei K. Assessment of glycemic control and variability in patients hospitalized with congestive heart failure during the implementation of hospital-wide initiatives and effects on mortality. Diabetes Metabol Res Rev 2011; 27: 85-93.
6. Eslami S, Taherzadeh Z, Schultz MJ, Abu-Hanna A. Glucose variability measures and their effect on mortality: a systematic review. Intensive Care Med 2011; 37: 583-593.
7. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-1354.
8. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability: does it matter? Endocr Rev 2010; 31: 171-182.
9. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.
10. Tang WH, Wu Y, Mann S, et al. Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. Circ Heart Fail 2011; 4: 59-64.
11. Santini V, Ciampittiello G, Gigli F, et al. QTc and autonomic neuropathy in diabetes: effects of acute hyperglycemia and n-3 PUFA. Nutr Metab Cardiovasc Dis 2007; 17: 712-718.
12. Koivikko ML, Salmela PI, Airaksinen KE, et al. Effects of sustained insulin-induced hypoglycemia on cardiovascular autonomic regulation in type 1 diabetes. Diabetes 2005; 54: 744-750.
13. Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. Cardiovasc Res 2006; 70: 434-445.
14. Panina G, Khot UN, Nunziata E, Cody RJ, Binkley PF. Role of spectral measures of heart rate variability as markers of disease progression in patients with chronic congestive heart failure not treated with angiotensin-converting enzyme inhibitors. Am Heart J 1996; 131: 153-157.
15. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98: 1510-1516.
16. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011; 34: 256-261.
17. Goldberg PA. Memoirs of a root canal salesman: the successful implementation of a hospital-wide intravenous insulin infusion protocol. Endocr Pract 2006; 12(Suppl 3): 79-85.
18. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004; 53: 955-962.
19. Zijlstra E, Heise T, Nosek L, Heinemann L, Heckermann S. Continuous glucose monitoring: quality of hypoglycaemia detection. Diabetes Obes Metab 2013; 15: 130-135.
20. Parthasarathy S. Modified Lipoproteins in the Pathogenesis of Atherosclerosis, RG Landers (ed.). Austin, TX, 1994; 91-119.
21. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.
22. Sherwood A, Allen MT, Fahrenberg J, Kelsey RM, Lovallo WR, van Doornen LJ. Methodological guidelines for impedance cardiography. Psychophysiology 1990; 27: 1-23.
23. Cacioppo JT, Berntson GG, Binkley PF, Quigley KS, Uchino BN, Fieldstone A. Autonomic cardiac control. II Noninvasive indices and basal response as revealed by autonomic blockades. Psychophysiology 1994; 31: 586-598.
24. Berntson GG, Bigger JT Jr, Eckberg DL, et al. Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology 1997; 34: 623-648.
25. Kalra PR, Anagnostopoulos C, Bolger AP, Coats AJ, Anker SD. The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol 2002; 39: 1901-1908.
26. Dungan K, Osei K, Sagrilla C, Binkley P. Effect of the approach to insulin therapy on glycemic fluctuations and autonomic tone in hospitalized patients with diabetes. Diabetes Obes Metab 2013; 15: 558-563.
27. Dungan KM, Osei K, Nagaraja HN, Schuster DP, Binkley P. Relationship between glycemic control and readmission rates in patients hospitalized with congestive heart failure during implementation of hospital-wide initiatives. Endocr Pract 2010; 16: 945-951.
28. Burger AJ, Aronson D. Blunted sympathetic response in diabetic patients with decompensated congestive heart failure. Int J Cardiol 2001; 81: 243-249.
29. Patel H, Ozdemir BA, Patel M, et al. Impairment of autonomic reactivity is a feature of heart failure whether or not the left ventricular ejection fraction is normal. Int J Cardiol 2011; 151: 34-39.